Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?

Bone Marrow Transplantation volume 48, pages 338–345 (2013)Cite this article

Subjects

Abstract

Renal dysfunction is a common complication of plasma cell myeloma (PCM) that may be severe enough to necessitate hemodialysis. Although high-dose chemotherapy and hematopoietic cell transplant (HCT) appears superior to conventional chemotherapy in likelihood of achieving CR and is associated with improvement in and, at times, reversal of renal dysfunction, many patients remain dialysis-dependent presenting the challenge of renal transplantation in this population. We reviewed the published literature and summarize the outcomes on dual organ (HCT and renal allograft) transplantation in patients with PCM and dialysis-dependent renal failure. In a literature review of 14 reports, 26 of 166 dialysis-dependent patients became dialysis-independent. Our review includes a very heterogenous patient population but suggests that HCT and renal allograft may be feasible in a subset of PCM patients with dialysis-dependent renal failure. Although there is a concern for renal allograft rejection upon withdrawal of immunosuppression, data suggest that resumption of antirejection therapy leads to stable renal function. Bortezomib potentially can be used as maintenance treatment in patients who have not achieved a CR while preventing renal allograft rejection. The literature that describes dual transplants has included patients with long-term follow-up (>7 years in some patients). It is possible, however, that there may be publication bias with only favorable results being reported. More research is necessary to further delineate the subset of PCM patients most likely to benefit from renal transplant. A special registry for data collection for long-term follow-up may be useful to improve future patient survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Kyle RA . Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50: 29–40.

    CAS  PubMed  Google Scholar 

  2. Rebibou JM, Caillot D, Casasnovas RO, Tanter Y, Maillard N, Solary E et al. Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Bone Marrow Transplant 1997; 20: 63–65.

    Article  CAS  PubMed  Google Scholar 

  3. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  4. DeFronzo RA, Cooke CR, Wright JR, Humphrey RL . Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978; 57: 151–166.

    Article  CAS  Google Scholar 

  5. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.

    Article  CAS  PubMed  Google Scholar 

  6. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE . Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990; 150: 863–869.

    Article  CAS  PubMed  Google Scholar 

  7. Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.

    Article  CAS  PubMed  Google Scholar 

  8. Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693–1695.

    Article  CAS  PubMed  Google Scholar 

  9. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.

    Article  CAS  PubMed  Google Scholar 

  10. Cohen DJ, Sherman WH, Osserman EF, Appel GB . Acute renal failure in patients with multiple myeloma. Am J Med 1984; 76: 247–256.

    Article  CAS  PubMed  Google Scholar 

  11. Cosio FG, Pence TV, Shapiro FL, Kjellstrand CM . Severe renal failure in multiple myeloma. Clin. Nephrol 1981; 15: 206–210.

    CAS  Google Scholar 

  12. Korzets A, Tam F, Russell G, Feehally J, Walls J . The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis 1990; 16: 216–223.

    Article  CAS  PubMed  Google Scholar 

  13. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  14. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  PubMed  Google Scholar 

  15. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385–390.

    Article  CAS  PubMed  Google Scholar 

  16. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812–816.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Reiter E, Kalhs P, Keil F, Rabitsch W, Gisslinger H, Mayer G et al. Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Ann Hematol 1999; 78: 189–191.

    Article  CAS  PubMed  Google Scholar 

  18. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renalfailure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    Article  CAS  PubMed  Google Scholar 

  19. Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N, Mahendra P . Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 2002; 30: 471–473.

    Article  CAS  PubMed  Google Scholar 

  20. Sorof JM, Koerper MA, Portale AA, Potter D, DeSantes K, Cowan M . Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation 1995; 59: 1633–1635.

    CAS  PubMed  Google Scholar 

  21. Jacobsen N, Taaning E, Ladefoged J, Kristensen JK, Pedersen FK . Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet 1994; 343: 800.

    Article  CAS  PubMed  Google Scholar 

  22. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL . Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114: 954–955.

    Article  CAS  PubMed  Google Scholar 

  23. Butcher JA, Hariharan S, Adams MB, Johnson CP, Roza AM, Cohen EP . Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant 1999; 13: 330–335.

    Article  CAS  PubMed  Google Scholar 

  24. Helg C, Chapuis B, Bolle J, Morel P, Salomon D, Boux E, Antonioli V et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation 1994; 58: 1420–1421.

    CAS  PubMed  Google Scholar 

  25. Sellers MTDM, Curtis JJ, Gaston RS, Julian BA, Lanier DC, Diethelm AG . Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow up. Transplantation 2001; 71: 1681–1683.

    Article  CAS  PubMed  Google Scholar 

  26. Gajewski JL, Ippoliti C, Ma Y, Champlin R . Discontinuation of immunosuppression for prevention of kidney graft rejection after receiving a bone marrow transplant from the same HLA identical sibling donor. Am J Hematol 2002; 71: 311–313.

    Article  PubMed  Google Scholar 

  27. Beitinjaneh A, Burns LJ, Majhail NS . Solid organ transplantation in survivors of hematopoietic cell transplantation: a single institution case series and literature review. Clin Transplant 24: E94–E102.

    Article  PubMed  Google Scholar 

  28. Hamawi K, De Magalhaes-Silverman M, Bertolatus JA . Outcomes of renal transplantation following bone marrow transplantation. Am J Transplant 2003; 3: 301–305.

    Article  PubMed  Google Scholar 

  29. Leung N, Griffin MD, Dispenzieri A, Haugen EN, Gloor JM, Schwab TR et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005; 5: 1660–1670.

    Article  PubMed  Google Scholar 

  30. Rego F, Alcantara P, Buinho F, Araujo F, Santos JM, Parreira A et al. Autologous peripheral stem cell transplantation for multiple myeloma in a patient with a 10 year-old kidney transplant: case report and clinical issues. Transplant Proc 2003; 35: 1102–1104.

    Article  CAS  PubMed  Google Scholar 

  31. Beatty PG . The immunogenetics of bone marrow transplantation. Transfus Med Rev 1994; 8: 45–58.

    Article  CAS  PubMed  Google Scholar 

  32. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–1777.

    Article  CAS  PubMed  Google Scholar 

  33. Mayumi H, Umesue M, Nomoto K . Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996; 195: 129–139.

    Article  CAS  PubMed  Google Scholar 

  34. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353–361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sharabi Y, Sachs DH . Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493–502.

    Article  CAS  PubMed  Google Scholar 

  37. Fuchimoto Y, Huang CA, Yamada K, Shimizu A, Kitamura H, Colvin RB et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000; 105: 1779–1789.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kawai TCA, Colvin RB, Powelson J, Eason J, Kozlowski T, Sykes M et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256–262.

    Article  CAS  PubMed  Google Scholar 

  39. Kawai T, Poncelet A, Sachs DH, Mauiyyedi S, Boskovic S, Wee SL et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68: 1767–1775.

    Article  CAS  PubMed  Google Scholar 

  40. Kawai T, Sogawa H, Boskovic S, Abrahamian G, Smith RN, Wee SL et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391–1398.

    Article  CAS  PubMed  Google Scholar 

  41. Kimikawa M, Kawai T, Sachs DH, Colvin RB, Bartholomew A, Cosimi AB . Mixed chimerism and transplantation tolerance induced by a nonlethal preparative regimen in cynomolgus monkeys. Transplant Proc 1997; 29: 1218.

    Article  CAS  PubMed  Google Scholar 

  42. Mezrich JD, Yamada K, Lee RS, Mawulawde K, Benjamin LC, Schwarze ML et al. Induction of tolerance to heart transplants by simultaneous cotransplantation of donor kidneys may depend on a radiation-sensitive renal-cell population. Transplantation 2003; 76: 625–631.

    Article  PubMed  Google Scholar 

  43. Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006; 6: 2121–2133.

    Article  CAS  PubMed  Google Scholar 

  44. Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR et al. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91: 672–676.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. US Renal Data System UADR. Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institure of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2009.

  46. Tyan DB, Li VA, Czer L, Trento A, Jordan SC . Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553–562.

    Article  CAS  PubMed  Google Scholar 

  47. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887–895.

    Article  CAS  PubMed  Google Scholar 

  48. Stegall MD, Gloor JM . Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 15: 8–10.

    Article  PubMed  Google Scholar 

  49. Terasaki PI . Humoral theory of transplantation. Am J Transplant 2003; 3: 665–673.

    Article  PubMed  Google Scholar 

  50. Adrogue HE, Soltero L, Land GA, Ramanathan V, Truong LD, Suki WN . Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft. Transplantation 2006; 82: 567–569.

    Article  CAS  PubMed  Google Scholar 

  51. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917.

    Article  CAS  PubMed  Google Scholar 

  52. Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653–656.

    Article  CAS  PubMed  Google Scholar 

  53. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642–648.

    Article  CAS  PubMed  Google Scholar 

  54. Carlson K . Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005; 35: 985–990.

    Article  CAS  PubMed  Google Scholar 

  55. Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008; 42: 405–412.

    Article  CAS  PubMed  Google Scholar 

  56. Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006; 91: 1555–1558.

    CAS  PubMed  Google Scholar 

  57. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 605–611.

    Article  CAS  PubMed  Google Scholar 

  58. Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310–1313.

    Article  CAS  PubMed  Google Scholar 

  59. Khoriaty R, Otrock ZK, Medawar WA, Khauli RB, Bazarbachi A . A case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma. Nephrol Dial Transplant 2006; 21: 3585–3588.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, OH, Cleveland, USA

    L Nayak & H M Lazarus

Authors
  1. L Nayak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H M Lazarus.

Ethics declarations

Competing interests

The authors declares no conflict of interest

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nayak, L., Lazarus, H. Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?. Bone Marrow Transplant 48, 338–345 (2013). https://doi.org/10.1038/bmt.2012.111

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.111

Keywords

This article is cited by

Search

Advanced search

Quick links